article thumbnail

#news #biotech PCR-test reveals risk of genotoxity of genome editing

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: PCR-test reveals risk of genotoxity of genome editing. from European Biotechnology – first and foremost in European biotech [link].

article thumbnail

A bioresorbable membrane for healing internal and external wounds

Medical Xpress

Fraunhofer researchers have succeeded in using the bioresorbable silica gel Renacer to produce an electrospun membrane that is neither cytotoxic to cells nor genotoxic.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Artificial Smoke Flavoring in Food: EU Ban and Industry Impact

XTalks

The ban, endorsed by member states in April 2024, follows scientific research indicating harmful chemicals in smoke flavorings. The ban targets artificial smoke flavorings linked to genotoxicity concerns. Genotoxicity involves damage to genetic material within cells, increasing cancer and inherited disease risks.

article thumbnail

The Composition and Value of a Portfolio Analysis

Camargo

Pediatric Research Equity Act (PREA) Requirements. A nonclinical safety evaluation program typically includes pharmacology, general toxicity, toxicokinetics, nonclinical PK, reproductive toxicity, genotoxicity, and carcinogenesis. Nonclinical Requirements. Chemistry, Manufacturing, and Controls (CMC) Strategies.

article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in vivo mammalian systems. “We Animals were administered molnupiravir for longer and at higher doses (mg/Kg) than those employed in human studies. About Molnupiravir.

Trials 69
article thumbnail

Moving off the critical path: Streamlining strategies for drug substance synthesis and manufacturing

Pharmaceutical Technology

Placing traditionally siloed drug substance and drug product development activities within a single organization that also has commercial manufacturing capabilities accelerates clinical development and builds in quality and robustness of supply.

article thumbnail

Packaging Solutions for Pharmaceuticals & Medical Devices: Insights and Considerations

XTalks

Curia is a global contract research, development and manufacturing organization (CDMO) that specializes in drug discovery, spanning the entire product lifecycle from target to lead candidate identification, development, manufacturing feasibility, through to commercialization and post-marketing. Analytical Instrumentation.